Last10K.com

Skye Bioscience, Inc. (SKYE) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

SKYE Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

SKYE Annual Reports

    10-K Annual Report March 2024
  • 10-K Annual Report March 2022
    • 10-K Annual Report March 2021

SKYE Quarterly Reports

SKYE Corporate News

SKYE Registration of Securities

Skye Bioscience, Inc.

HISTORY TOOLS
CIK: 1516551 Ticker: SKYE
Cover - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 24, 2022
Jun. 30, 2021
Cover [Abstract]   
Document Type10-K  
Document Annual Reporttrue  
Document Period End DateDec. 31, 2021  
Current Fiscal Year End Date--12-31  
Document Transition Reportfalse  
Entity File Number000-55136  
Entity Registrant NameSkye Bioscience, Inc.  
Entity Incorporation, State or Country CodeNV  
Entity Tax Identification Number45-0692882  
Entity Address, Address Line One11250 El Camino Real  
Entity Address, Address Line TwoSuite 100  
Entity Address, City or TownSan Diego  
Entity Address, State or ProvinceCA  
Entity Address, Postal Zip Code92130  
City Area Code858  
Local Phone Number410-0266  
Title of 12(g) SecurityCommon Stock, Par Value $0.001  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
Entity Shell Companyfalse  
Entity Public Float  $ 45,310,946
Entity Common Stock, Shares Outstanding 495,925,112 
Entity Central Index Key0001516551  
Amendment Flagfalse  
Document Fiscal Year Focus2021  
Document Fiscal Period FocusFY  

View differences made from one year to another to evaluate Skye Bioscience, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Skye Bioscience, Inc..

Continue

Assess how Skye Bioscience, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Skye Bioscience, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover
Consolidated Balance Sheets
Consolidated Balance Sheets (Parentheticals)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (Parentheticals)
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Stockholders' Equity
Consolidated Statements Of Stockholders' Equity (Parentheticals)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Current And Noncurrent Portions Of Operating Lease (Details)
Commitments And Contingencies - Narrative (Details)
Commitments And Contingencies - Schedule Of Future Minimum Lease Payments (Details)
Commitments And Contingencies - Weighted Average Remaining Lease Term And Discount Rate (Details)
Debt
Debt (Tables)
Debt - Interest Expense (Details)
Debt - Narrative (Details)
Debt - Schedule Of Debt (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Components Of Income (Loss) Before The Income Tax Provision (Benefit) (Details)
Income Taxes - Deferred Income Tax Assets (Details)
Income Taxes - Narrative (Details)
Income Taxes - Provision For Income Taxes On Earnings (Details)
Income Taxes - Unrecognized Tax Positions (Details)
Loss Per Share Of Common Stock
Loss Per Share Of Common Stock (Tables)
Loss Per Share Of Common Stock - Anti-Dilutive Securities (Details)
Loss Per Share Of Common Stock - Basic And Diluted Net Loss Per Share (Details)
Nature Of Operations And Business Activities
Nature Of Operations And Business Activities (Details)
Other Current Liabilities
Other Current Liabilities (Details)
Other Current Liabilities (Tables)
Related Party Matters
Related Party Matters (Details)
Significant Contracts - University Of Mississippi
Significant Contracts - University Of Mississippi (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Fair Value Assumptions Of Stock Option Granted (Details)
Stock-Based Compensation - Narrative (Details)
Stock-Based Compensation - Restricted Stock Awards (Details)
Stock-Based Compensation - Shares Available For Future Grant (Details)
Stock-Based Compensation - Stock-Based Compensation Expense (Details)
Stock-Based Compensation - Summary Of Option (Details)
Stockholders' Equity And Capitalization
Stockholders' Equity And Capitalization (Tables)
Stockholders??? Equity And Capitalization - Narrative (Details)
Stockholders??? Equity And Capitalization - Reserved Shares Of Common Stock (Details)
Subsequent Events
Subsequent Events (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Warrants And Derivative Liabilities
Warrants And Derivative Liabilities (Tables)
Warrants And Derivative Liabilities - Derivative Liabilities (Details)
Warrants And Derivative Liabilities - Narrative (Details)
Warrants And Derivative Liabilities - Schedule Of Input And Valuation Techniques Used To Value Warrant Liabilities (Details)
Warrants And Derivative Liabilities - Schedule Of Warrants Vested And Outstanding (Details)
Ticker: SKYE
CIK: 1516551
Form Type: 10-K Annual Report
Accession Number: 0001516551-22-000004
Submitted to the SEC: Fri Mar 25 2022 7:38:51 PM EST
Accepted by the SEC: Mon Mar 28 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/skye/0001516551-22-000004.htm